In phase 3 SANOVO, savolitinib + osimertinib (Tagrisso) extended median PFS to 24.9 months vs 13.8 months with osimertinib alone in the overall study population.
@myesmo.bsky.social #ESMO36 #lcsm

🔗 Read more: www.onclive.com/view/savolit...